Inspire Medical Systems, Inc.

NYSE INSP

Inspire Medical Systems, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD 19.44 M

Inspire Medical Systems, Inc. EBIT is USD 19.44 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 138.43% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Inspire Medical Systems, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -50.58 M, a -5.47% change year over year.
Inspire Medical Systems, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -47.96 M, a -6.01% change year over year.
Inspire Medical Systems, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -45.24 M, a 20.01% change year over year.
Inspire Medical Systems, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -56.56 M, a -112.12% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NYSE: INSP

Inspire Medical Systems, Inc.

CEO	Mr. Timothy P. Herbert
IPO Date	May 3, 2018
Location	United States
Headquarters	5500 Wayzata Boulevard
Employees	1,011
Sector	Health Care
Industries Telehealth Pharmaceuticals

Description

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Key trends

Past 5 years